Bet against BSX on this ruling: the preliminary injunction denial opens the door for Stryker's OptaBlate to compete in the BVN ablation market, eroding BSX's current monopoly position (Relievant Medsystems' Intracept product). Watch for the upcoming claim construction hearing and any settlement developments. Stryker shares may see a modest positive reaction from removed near-term launch risk.
How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 18 $45.29entry
- T+1 · 5mo ago −2.12%α −1.80% · $44.33
- T+5 · 5mo ago −2.34%α +0.04% · $44.23
- T+20 · 4mo ago −3.36%α −2.73% · $43.77
- T+60 · 2mo ago −3.14%α −4.56% · $43.87
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
The Federal Circuit affirmed the District of New Jersey's denial of Boston Scientific's (BSX) motion for a preliminary injunction that would have blocked Stryker (SYK) from launching its OptaBlate BVN device. The appeals court found substantial questions regarding whether Stryker induces infringement of BSX's '166 patent, specifically whether the accused device's access cannula 'reaches' the cancellous bone as required. The ruling clears a near-term competitive threat to Stryker but keeps the underlying patent case alive for a full trial on the merits.
Court Ruling Details
Key Facts
- Federal Circuit affirmed denial of preliminary injunction against Stryker's OptaBlate BVN device.
- Court held there are substantial questions of fact regarding whether Stryker induces infringement of claims 16 and 21 of U.S. Patent No. 12,303,166.
- District court's tentative claim construction that 'reaches' means 'touches or extends to' the cancellous bone was not an abuse of discretion.
- Evidence of Stryker's physician instructions was ambiguous, slides, imaging, and IFU diagrams did not clearly show direct infringement.
- Doctrine of equivalents argument was forfeited below and insufficiently supported; conflicting expert testimony raised substantial questions.
- District court has a claim construction hearing scheduled for further proceedings; the case will continue on the merits.
- Pre-filing news discount likely applies, Stryker had announced FDA clearance and plans to market OptaBlate BVN before the filing, so some market impact may be priced in.
Financial Impact
Lost opportunity to block a competing product (OptaBlate BVN) in the basivertebral nerve ablation market; no damages awarded or financial figures stated in the ruling.
Risk Factors
- BSX could still win at trial or on a revised claim construction, full merits phase remains.
- Stryker's OptaBlate launch may be delayed by other regulatory or manufacturing issues.
- Appeal to SCOTUS is unlikely given nonprecedential Federal Circuit affirmance.
- Market may have already priced in competitive launch risk, diminished incremental impact.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 court opinion.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-1agfa85l-BSX |
Track record
22 reports on BSX
3 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +9.24% at T+20 after the Aug 26, 2026 report. 6 of 8 went positive at some point.
Filters
- Oct 28, 202619d ago 8-K Bearish 6/10 No price data
- Oct 28, 202619d ago Press Release Bearish 5/10 Entry $42.43 Now $43.79 −3.21% settles Nov 25
- Oct 23, 202624d ago Institutional Cluster Bearish 4/10 Entry $45.69 Now $43.79 +4.16% settles Nov 20
- Oct 7, 20265w ago 8-K Mixed 6/10 Entry $41.58 to $45.82 Now $43.79 +5.32% ▲ +10.20% +11.54% vs SPY
- Sep 23, 20267w ago 8-K Bearish 5/10 Entry $44.62 to $44.51 Now $43.79 +1.86% ▲ +0.25% +0.93% vs SPY
- Aug 31, 202611w ago Court Ruling Neutral 2/10 Entry $48.08 to $43.65 Now $43.79 −8.92% ▼ −9.21% −9.57% vs SPY
- Aug 26, 202611w ago 8-K Bearish 6/10 Entry $48.17 to $43.72 Now $43.79 +9.09% ▲ +9.24% +10.44% vs SPY
- Aug 22, 202612w ago Institutional Cluster Mixed 6/10 Entry $49.01 to $44.92 Now $43.79 −10.65% ▼ −8.35% −9.66% vs SPY
- Aug 7, 202614w ago Insider Cluster Mixed 6/10 Entry $50.46 to $44.98 Now $43.79 −13.22% ▼ −10.86% −9.95% vs SPY
- Aug 7, 202614w ago Insider Cluster Mixed 5/10 Entry $50.46 to $44.98 Now $43.79 −13.22% ▼ −10.86% −9.95% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more, parsed and scored by AI.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers